Susan R. Rheingold, MD

Susan R. Rheingold, MD, is medical director of the Oncology Outpatient Clinic and an attending physician with the Cancer Center at CHOP.

Areas of Expertise: Acute lymphoblastic leukemia, Complementary and alternative medicine, Medical education, Non-Hodgkins lymphoma
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Background

    Susan R. Rheingold, MD, is an attending physician, Department of Pediatrics, Division of Oncology, at The Children’s Hospital of Philadelphia and associate professor in Pediatrics at the University of Pennsylvania School of Medicine.

    A 1992 graduate of the University of Pennsylvania School of Medicine, Dr. Rheingold completed a residency in pediatrics at John Hopkins Hospital in Baltimore, Maryland and a fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia.

    After completing her training in 1999, Dr. Rheingold joined the staff of Children’s Hospital. She currently serves as the Medical Director of the Oncology outpatient clinic and director of Oncology Education for the Division of Oncology.

    Dr. Rheingold’s expertise is in the diagnosis, treatment and biology of acute lymphocytic leukemia (ALL). She serves on the Children’s Oncology Group’s Relapsed ALL Committee, Infant ALL Committee, and the Complementary Therapies Committee. Besides ALL, Dr. Rheingold maintains a special interest in experimental therapeutics and serves as a principal investigator for a Children’s Oncology Group national protocol.

    Other interests include complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education and rare childhood tumors. Dr. Rheingold is board certified in Pediatrics as well as Pediatric Hematology/Oncology.

  • Education and Training

    Medical School

    MD - University of Pennsylvania School of Medicine, Philadelphia, PA

    Internship

    Peditarics - Johns Hopkins Hospital, Baltimore MD

    Residency

    Pediatrics - Johns Hopkins Hospital, Baltimore MD

    Fellowship

    Pediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA

    Board Certification

    Pediatric Hematology-Oncology
    Pediatrics

  • Titles and Academic Titles

    Medical Director, Oncology Outpatient Clinic

    Attending Physician

    Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Departments and Services
  • Research Interests

    Clinical research on relapsed leukemia
    Supportive Care Trials
    Experimental Drug Trials for ALL

  • Publications

    Books

    Chapters

    2015

    Sacks N, Henry D, Rheingold SR. Oncology, Hematopoietic Transplant, Gastrointestinal Supportive Care Medications and Survivorship. In: A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. M.A. Corkins ed. American Society for Parenteral and Enteral Nutrition, 2015

    2013

    Fisher M, Balamuth N, Rheingold SR. Basics Of Pediatric Anesthesia, In: Oncologic Diseases, 2nd Ed.,  RS Litman ed. Lippincott, Williams, and Wilkins, 2013

    2012

    Rheingold SR. The 5 Minute Pediatric Consult, 5th Ed. M.W. Schwartz ed.   Williams & Wilkins. Leukocytosis , Acute Lymphoblastic Leukemia, 2012

    2011

    Green A, Rheingold SR. Leukemia. In: Netter’s Pediatrics, 1st Ed., T Florin and S Ludwig, eds. Elsevier Health Sciences, 2011

    Fisher M, Rheingold SR. Oncologic Emergencies. In: Principles and Practice of Pediatric Oncology, 6th Ed. P.A. Pizzo and D.G.Poplack eds. Lippincott, Williams, and Wilkins, 2011

    Wolfe L, Scerbo J, Rheingold SR. Management of Oncologic Emergencies. In: Manual of Pediatric Hematology and Oncology, 5th Ed., P. Lanzowsky ed. Elsevier Health Sciences, 2011.

    2010

    Rheingold SR. Oncologic emergencies. In: Davis DH, editor. Pediatric critical care: the requisites in pediatrics. Philadelphia: Elsevier Health Sciences-Mosby.

    Bailey C, Felix C, Rheingold SR. Acute lymphoblastic leukemia. In: Brodeur GM, Manno CS, editors. Pediatric hematology/oncology: the requisites in pediatrics. Philadelphia: Elsevier-Mosby.

    Teachey D, Bunin N, Rheingold SR. Germ cell tumors. In: Brodeur GM, Manno CS, editors. Pediatric hematology/oncology: the requisites in pediatrics. Philadelphia: Elsevier-Mosby.

    Fisher M, Rheingold SR. Oncologic emergencies. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2010.

    Green A, Rheingold SR. Leukemia. In: Florin T, Ludwig S, editors. Netter's pediatrics. 1st ed. Philadelphia: Elsevier Health Sciences; 2010.

    Wolfe L, Scerbo J, Rheingold SR. Management of oncologic emergencies. In: Lanzowsky P, editor. Manual of pediatric hematology and oncology. 5th ed. Philadelphia: Elsevier Health Sciences. 2010.

    Sacks N, Wallace E, Bogucki B, Guzikowski V, Henry D, Rheingold SR. Hematology/oncology and hematopoietic transplant. In: Corkins M, editor. Pediatric nutrition support core curriculum. 1st ed. Silver Spring: American Society of Pediatric Enteral Nutrition (A.S.P.E.N.); 2010, p. 349.

    2009

    Rheingold SR, Neugut AI, Uldrick T, Meadows AT. Treatment-related secondary cancers. In: Hong WK, Bast RC, Hait WN, Kufe DW, Pollack RE, Weichselbaum RR, Holland JF, Frei EF, editors. Holland-Frei Cancer medicine. 8th ed. Shelton: People's Medical Publishing House; 2009. p. 1915.

    2006

    Rheingold SR, Neugut AI, Meadows AT. Treatment-related secondary cancers In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Hait W, Hong WK, Holland JF, Frei E, editors. Cancer medicine. 7th ed. Shelton: People's Medical Publishing House-USA; 2006.

    2005

    Rheingold SR, Lange BJ. Oncologic emergencies. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1202-30.

    Rheingold SR, Lange BJ. Oncologic emergencies. In: Fleisher GR, Ludwig S, editors. Textbook of pediatric emergency medicine. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1239-74.

    Abstracts

    2015

    Rheingold SR, Whitlock JA, Tasian SK, Teachey DT, Borowitz MJ, Lui X, Ahern CA, Minard CG, Fox E, Weigel BJ, Blaney SM. Temsirolimus and Intensive Re-induction Chemotherapy for 2nd or Greater Relapse of Acute Lymphoblastic Leukemia (ALL): a Children's Oncology Group Study (ADVL1114).  ASCO 2015

    Gurunathan A, Desai AV, Bailey LC, Li Y, Choi J, Rheingold SR. Identification of patients with post-induction CNS 2 status and outcomes in acute lymphoblastic leukemia. ASCO 2015

    2014

    Stackelberg AV, Locatelli F, Zugmaier G, Handgretinger R, Trippet TM, Rizzari C, Zwaan CM, Bhojwani D, Dubois SG, Bader P, Borkhardt A, O’Brien MM, Rheingold SR,  Cooper TM, Hu K, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. Phase ½ study in pediatric patients with relapsed/refractory b-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH 2014

    Aplenc R, Barrett D, Callahan C, Chew A, Grupp S, June C, Lacey S, Levine B, Maude S, Melenhorst J, Motley L, Porter D, Rheingold S, Shaw P, Shen A, Teachey D, Wood P. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. ASH 2014

    Weili S, Smith A, Orgel E, Sposto R, Wilkes JJ, Gardner R, Hur Minjun, Pineros V, Olson E, Tan Y, Rheingold SR, Burke M, Wayne AS. The UK ALLR3 (R3) chemotherapy regimen for relapsed/refractory acute lymphoblastic leukemia (ALL) of childhood: A multi-institutional retrospective study of treatment related adverse events. ASH 2014

    Lew G, Lu X, Yanofsky RA, Rheingold SR, Whitlock JA, An Q, Devidas M, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger SP, Pulsipher MA. Outcomes after intermediate-risk relapse of childhood B-lymphoblastic leukemia (B-ALL) and the role of allogeneic stem cell transplantation (SCT): A report from children’s oncology group (COG) AALL0433. ASH 2014

    Lew G, Lu X, Yanofsky, Rheingold SR, Whitlock J, Gulig SD, Devidas M, Pulsipher M, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger S. The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433. ASCO 2014

    Wilkes JJ, Xiao R, Seif AE, HuangYS, Vendetti ND, Rheingold SR, Aplenc R, Hennessy A, Fisher B. Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume. ASCO 2014

    Whitlock J, Stackelberg AV, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, O’Brien MM, Rheingold SR, Gore L. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase I/II study. SIOP 2014

    Grupp, S, Frey N, Aplenc R, Levine B, Maude S, Rheingold SR, Barker CS, Teachey D, Mahnke Y, Porter D, June C. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019 cells) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. EBMT 2014

    Locatelli F, Gore L, Zugmaier G, Handgretinger R, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR,  Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Stackelberg AV. Blinatumomab in pediatric  patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL): a phase I/II study. EBMT  2014

    2013

    Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Lichtman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey D, Wood P, Porter D, June CH. T cells engineered with a chimeric antigen receptor (CAR) targeting CD 19 (CTL 019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. ASH 2013.

    von Stacklberg A, Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. ASH 2013.

    von Stacklberg A, Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. ASH 2013.

    Plourde PV, Jeha S, Hijiya N, Keller F, Rheingold SR, Dreyer Z, Dahl G, Mercedes T, Corn T. Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient population. ASCO 2013.

    Papers

    2015

    Johnson L, Leek AC, Drotar D, Noll RB, Rheingold SR, Kodish ED, Baker JN. Practical communication guidance to improve phase I informed consent conversations and end-of-life decision-making in pediatric oncology.  Cancer, 2015; epub April.

    2014

    Shannon ML, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 2014;371(16):1507-17.

    Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer, 2014; 61(7):1232-8.

    Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang Y-S, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc RA. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatric Critical Care Medicine, 2014 15(2):112-20.

    Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YV, Harris T, Shah A, Hall M, Fieldston E, Vujkovic M, Bailey C, Kersun LS, Reilly AF, Rheingold SR, Walker DS, Aplenc R. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer, 2014;61(5):846-52.

    Sacks N, Hwang W-T, Lange BJ, Tan K-S, Sandler ES, Rogers PC, Womer RB, and Rheingold SR. Proactive enteral tube feeding in pediatric patients undergoing chemotherapy. Pediatr Blood Cancer, 2014; 61(2):281-5.

    2013

    Lothstein K, Fisher B, Li Y, Seif AE, Harris T, Torp K, Kavcic M, Huang YS, Rheingold SR, Aplenc R. Zoonotic infections in pediatric patients with acute leukemia. Pediatr Blood Cancer, 2013;60(12):E160-2.

    Baker JN, Leek AC, Showalter Salas H, Gibson D, Drotar D, Noll R, Rheingold SR, Kodish ED. Suggestions from adolescent, young adult, and parents for improving informed consent in Phase I pediatric oncology trials. Cancer, 2013;60(5):873-8.

    Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Aplenc KR, Gore L, and Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood, 2013;121(26):5154-7.

    Borst AJ, States LJ, Reilly AF, Rheingold SR. Determining response and recurrence in pediatric B-Cell lymphomas of the bone. Pediatr Blood Cancer, 2013;60(8):1281-6.

    Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 2013; 368(16):1509-18.

    Miller VA,  Baker JN, Leek AC,  Hizlan S, Rheingold, SR, Yamokoski AD, Drotar D, Kodish E. Adolescent perspectives on Phase I cancer research. Pediatr Blood Cancer, 2013;60(5):873-78.

    Posters and Presentations

     

    Invited Lectures

    2015

    "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia”, MOC Session presenter- ASPHO, Phoenix, AZ, May 2015.

    Federal Drug Administration Presenter and Panelist, “New Drugs: Breakthrough Therapies and Beyond”- AACR, Philadelphia, PA, April 2015.

    2014

    Session Moderator, “What’s all the Buzz about Targeted Immunotherapies for B-Cell Malignancies”- ASPHO, Chicago, IL, May 2014.

    2013

    “Pediatric ALL: Update on Treatment and Follow-up Care” - Leukemia & Lymphoma Society Telephone/Web Education Program, National Teleconference, November 2013.

    “A Phase 1 Study of Temsirolimus in Combination with Etoposide & Cyclophosphamide in Children with Relapsed ALL and NHL” - Therapeutic Advances in Childhood Leukemia Annual Meeting, Chicago, IL, September 2013.

    “The First Five ALL Patients Treated with Chimeric Antigen Receptor-Modified T-cells (CART)” - ALL Study Chair Affinity Group, International Teleconference, May 2013.

    “Childhood Cancer” - Congreso Interamericano de Pediatria, Starmedica Conference, Mexico City, Mexico, January 2013.

  • Awards and Honors

    2007, Leader of Family-Centered Care in Action, Voted by Staff and Families, CHOP
    2005, 2007, 2008, 2010, 2013, Top Doctor, Philadelphia Magazine
    2002, 2005, 2007, 2013, Faculty Honor Roll, Voted by Residents, CHOP
    2002, Selected Participant, AAMC Early Career Women Faculty Professional Development Seminar
    2001, Selected Participant, Federation of European Cancer Societies, AACR, ASCO, Methods in Clinical Cancer Research: Flims, Switzerland
    1999, Young Investigator Award, American Society of Clinical Oncology: Control of B Lymphocyte Development by Pre-B Cell Receptor-Mediated Signaling
    1998, Selected Participant, American Association for Cancer Research Workshop, Molecular Biology in Clinical Oncology: The Given Institute, Aspen, CO
    1988, B.A. Magna Cum Laude, Dartmouth College, Hanover, NH
    1988, Phi Beta Kappa, Dartmouth College, Hanover, NH
    1986-1988, Green Key Society, Dartmouth College, Hanover, NH
    1986-1988, Rufus Choate Scholar, Dartmouth College, Hanover, NH

  • Editorial and Academic Positions

    Editorial positions

    Reviewer 

    British Journal of Hematology
    Journal of Pediatrics
    Journal of Pediatric Hematology/Oncology
    Pediatric Blood & Cancer
    Clinical Cancer Research

    Academic and Institutional Committees

    2013-present, Rapid Improvement Task Force, Center for Quality and Patient Safety
    2008-present, Division of Oncology Pediatric Protocol Review Committee
    2002-present, HIM Documentation Committee
    2001-present, Admissions Committee, Perelman School of Medicine

  • Leaderships

    Memberships in Professional Organizations

    American Society of Clinical Oncology
    American Society of Hematology
    American Society of Pediatric Hematology/Oncology
    Children’s Oncology Group